Payment overview · 2025
General Payments
$5,231.25
212 reported records · 28 companies
Healthcare provider profile · identity verified
Mark Robert Honzel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Addiction Medicine · BEVERLY HILLS, CA · NPI 1083761670
Verified facts
What the public records show
CMS Open Payments records show Mark Robert Honzel, M.D. received $5,231.25 in general payments during 2025 across 212 reported records.
ABBVIE INC. accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Mounjaro, Relistor, Rexulti, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Descovy by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Gamunex-C by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Relistor by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $688.50 | 13.2% | 29 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $589.06 | 11.3% | 26 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $552.58 | 10.6% | 27 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $460.28 | 8.8% | 16 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $420.84 | 8.0% | 15 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $329.88 | 6.3% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $325.52 | 6.2% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $307.62 | 5.9% | 15 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $220.88 | 4.2% | 8 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $219.06 | 4.2% | 7 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $172.03 | 3.3% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $118.46 | 2.3% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $99.73 | 1.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $92.41 | 1.8% | 3 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $88.12 | 1.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.28 | 1.5% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.56 | 1.5% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $54.81 | 1.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.45 | 0.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.20 | 0.8% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $44.08 | 0.8% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.78 | 0.8% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $30.62 | 0.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $29.70 | 0.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $28.91 | 0.6% | 1 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $23.44 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.35 | 0.4% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $21.10 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,231.25 | 212 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $688.50 | 29 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $589.06 | 26 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $460.28 | 16 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $418.69 | 20 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $405.80 | 17 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $329.88 | 12 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $260.58 | 13 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $219.06 | 7 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $219.06 | 7 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $196.84 | 7 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $146.93 | 5 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $133.89 | 7 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $118.46 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $99.73 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $92.41 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $88.53 | 3 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $88.12 | 3 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $83.50 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $78.56 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $77.07 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.04 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.20 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.20 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $44.08 | 2 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $30.62 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $29.70 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
182 | 14 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
169 | 15 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 195 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 189 | 19 |
| Serostim | Somatropin | 182 | 14 |
| Gabapentin | Gabapentin | 176 | 29 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 169 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 19 |
| Ibuprofen | Ibuprofen | 158 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 23 |
| Losartan Potassium | Losartan Potassium | 138 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 21 |
| Metformin Hcl | Metformin Hcl | 125 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 118 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 12 |
| Buprenorphine Hcl | Buprenorphine Hcl | 104 | 12 |
| Alprazolam | Alprazolam | 103 | 13 |
| Bupropion Xl | Bupropion Hcl | 102 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 100 | 13 |
| Trazodone Hcl | Trazodone Hcl | 98 | 17 |
| Meloxicam | Meloxicam | 96 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | 12 |
| Diazepam | Diazepam | 89 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 21 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 86 | 12 |
| Valacyclovir | Valacyclovir Hcl | 85 | 13 |
| Finasteride | Finasteride | 84 | 14 |
| Tivicay | Dolutegravir Sodium | 82 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 12 |
| Jardiance | Empagliflozin | 75 | suppressed |
| Memantine Hcl | Memantine Hcl | 67 | 11 |
| Armodafinil | Armodafinil | 62 | suppressed |
| Clonazepam | Clonazepam | 59 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | suppressed |
| Eszopiclone | Eszopiclone | 58 | suppressed |
| Famotidine | Famotidine | 58 | 11 |
| Testosterone | Testosterone | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | suppressed |
| Ezetimibe | Ezetimibe | 53 | suppressed |
| Lorazepam | Lorazepam | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 50 | suppressed |
| Relistor | Methylnaltrexone Bromide | 49 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 48 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Omeprazole | Omeprazole | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 26 |
| Ondansetron Odt | Ondansetron | 39 | 12 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 23 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ritonavir | Ritonavir | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Darunavir | Darunavir | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 19 | 19 |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Androgel | Testosterone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,231.25 · 212 records | ABBVIE INC. | APRETUDE, ARISTADA, Auvelity, CABENUVA, CAPLYTA, CAPVAXIVE, COBENFY, DOVATO, ERZOFRI EXTENDED-RELEASE, FANAPT, Gamunex-C, INGREZZA, INVEGA SUSTENNA, JATENZO, LOREEV XR, LYBALVI, MOUNJARO, Mytesi, OTEZLA, PIFELTRO, Qelbree, RELISTOR, REPATHA, REXULTI, SPRAVATO, SUBLOCADE, Sunosi, TRINTELLIX, TRULANCE, UZEDY, VRAYLAR, VYVGART HYTRULO, WELLBUTRIN, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error